Emergent BioSolutions Inc. (EBS)

Market Cap	658.03M
Revenue (ttm)	1.51B
Net Income (ttm)	53.50M
Shares Out	49.89M
EPS (ttm)	0.78
PE Ratio	16.91
Forward PE	7.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	808,051
Open	13.00
Previous Close	12.92
Day's Range	13.00 - 13.40
52-Week Range	10.61 - 47.71
Beta	0.89
Analysts	Buy
Price Target	31.11 (+135.86%)
Earnings Date	Feb 23, 2023

About EBS

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat b...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 15, 2006
• Employees: 2,416
• Stock Exchange: NYSE
• Ticker Symbol: EBS

Financial Performance

In 2021, EBS's revenue was $1.79 billion, an increase of 15.26% compared to the previous year's $1.56 billion. Earnings were $230.90 million, a decrease of -24.32%.

Analyst Forecast

According to 11 analysts, the average rating for EBS stock is "Buy." The 12-month stock price forecast is $31.11, which is an increase of 135.86% from the latest price.

Price Target

$31.11

(135.86% upside)

Analyst Consensus: Buy